Ferreri AJM, Angelillo P, Erbella F, et al. - In this retrospective series, researchers reported outcomes of consecutive patients (pts) with Burkitt lymphoma (BL) or high-grade B-cell lymphoma with MYC rearrangement (HGBCL) treated with a new dose-dense, short-term therapy termed “CARMEN”. Participants were either HIV-negative and HIV-positive pts aged 18-80 years who were suffering from BL or HGBCL and MYC rearrangement positive by FISH. These patients underwent CARMEN regimen, which includes a single 36-day induction course of sequential doses of cyclophosphamide, vincristine, rituximab, methotrexate, VP16, and doxorubicin plus intrathecal chemotherapy, followed by consolidation with HD-cytarabine ± cisplatin. Those who failed to attain complete remission post-induction received BEAM/ASCT following consolidation. Findings demonstrated safety as well as activity of CARMEN treatment both in HIV-negative and –positive pts with HGBCL and MYC rearrangement and BL. Survival figures in HGBCL pts compared favorably with outcomes noted with R-CHOP or analogous, and were shown to be similar to those obtained in BL pts.